ProQR Therapeutics announces successful defense of Axiomer patent pending

ProQR Therapeutics announced it has successfully defended against two oppositions that were filed against a key patent for its ADAR-mediated RNA editing platform Axiomer. The oppositions were filed in February 2021 with the European Patent Office by two separate strawmen against ProQR’s granted patent EP 3234134 B1, which is related to targeted RNA editing using endogenous ADARs and is part of ProQR’s intellectual property estate surrounding its Axiomer RNA editing platform. The Opposition Division of the EPO held a public hearing on March 7 and 8, 2023 and ruled in favor of ProQR’s position, after a minor amendment of the main claim and one dependent claim. "ProQR owns a robust intellectual property portfolio protecting its Axiomer ADAR-mediated RNA editing platform technology platform. This successful defense of opposition against a key Axiomer patent is an important validation of the strength of our patent estate and confirms our leading IP position in the field," said Rene Beukema, Chief Corporate Development Officer and General Counsel. "We are confident about our leading IP estate and look forward to continuing to advance our Axiomer RNA editing technology platform to ultimately benefit patient communities with unmet need".